Literature DB >> 12655091

A glucocorticoid response element in the LTR U3 region of Friend murine leukaemia virus variant FIS-2 enhances virus production in vitro and is a major determinant for sex differences in susceptibility to FIS-2 infection in vivo.

Torunn Bruland1, Liss Anne S Lavik2, Hong Yan Dai2, Are Dalen2,1.   

Abstract

The nucleotide sequence of the Friend murine leukaemia virus variant FIS-2 LTR has high identity with the closely related Friend murine leukaemia virus (F-MuLV) LTR, except for the deletion of one direct repeat, a few point mutations and the generation of a glucocorticoid response element (GRE) in the U3 region. The GRE can mediate gene induction by glucocorticoids, mineral corticoids, progesterone and androgens, and it has been shown that incorporation of a GRE(s) within the LTR can increase the transcriptional activity of retroviral enhancers. We have previously reported an increased early virus replication in male mice compared with female mice when infected with a virus containing the FIS-2 LTR and have proposed that the GRE might contribute to this sex difference. In the present study, we introduced a single point mutation in the GRE and performed comparative studies in NIH 3T3 cells and in young adult male and female NMRI mice. We found that significantly more virus was produced from NIH 3T3 cells infected with wt FIS-2 than from cells infected with the FIS-2 GRE mutant and that this difference was further augmented by glucocorticoids. The glucocorticoid antagonist RU486 inhibited virus production in a dose-dependent manner. The wt FIS-2 disseminated significantly faster than the FIS-2 GRE mutant in both male and female mice. There was no significant difference in the dissemination rate between male and female mice infected with the FIS-2 GRE mutant. Hence, the GRE in the FIS-2 LTR is one determinant of the significant sex difference in susceptibility to FIS-2 infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12655091     DOI: 10.1099/vir.0.18625-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Control of pathogenicity and disease specificity of a T-lymphomagenic gammaretrovirus by E-box motifs but not by an overlapping glucocorticoid response element.

Authors:  Ditte Ejegod; Karina Dalsgaard Sørensen; Ilona Mossbrugger; Leticia Quintanilla-Martinez; Jörg Schmidt; Finn Skou Pedersen
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

2.  Dexamethasone and mifepristone increase retroviral infectivity through different mechanisms.

Authors:  Victor Solodushko; Vira Bitko; Brian Fouty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-06-26       Impact factor: 5.464

3.  Dexamethasone transcriptionally increases the expression of the pregnane X receptor and synergistically enhances pyrethroid esfenvalerate in the induction of cytochrome P450 3A23.

Authors:  Deshi Shi; Dongfang Yang; Bingfang Yan
Journal:  Biochem Pharmacol       Date:  2010-07-01       Impact factor: 5.858

4.  Androgen stimulates transcription and replication of xenotropic murine leukemia virus-related virus.

Authors:  Beihua Dong; Robert H Silverman
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

5.  Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant.

Authors:  Anatoly Urisman; Ross J Molinaro; Nicole Fischer; Sarah J Plummer; Graham Casey; Eric A Klein; Krishnamurthy Malathi; Cristina Magi-Galluzzi; Raymond R Tubbs; Don Ganem; Robert H Silverman; Joseph L DeRisi
Journal:  PLoS Pathog       Date:  2006-03-31       Impact factor: 6.823

6.  Defining differential genetic signatures in CXCR4- and the CCR5-utilizing HIV-1 co-linear sequences.

Authors:  Benjamas Aiamkitsumrit; Will Dampier; Julio Martin-Garcia; Michael R Nonnemacher; Vanessa Pirrone; Tatyana Ivanova; Wen Zhong; Evelyn Kilareski; Hazeez Aldigun; Brian Frantz; Matthew Rimbey; Adam Wojno; Shendra Passic; Jean W Williams; Sonia Shah; Brandon Blakey; Nirzari Parikh; Jeffrey M Jacobson; Brian Moldover; Brian Wigdahl
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.